BioSpace News Archive

Meridian Bioscience, Inc., a leading global provider of diagnostic testing solutions and life science raw materials, announced today that the United States Food and Drug Administration (FDA) has cleared Premier® HpSA® FLEX™ for the diagnosis of H. pylori in both preserved and unpreserved stools.

23andMe Holding Co. announced that it will report financial results for the fiscal year 2024 first quarter after the market closes on Tuesday, August 8, 2023.

Aquestive Therapeutics, Inc. (NASDAQ: AQST), (the “Company” or “Aquestive”) today announced that it will report results for the second quarter ended June 30, 2023, and provide an update on recent developments in its business after market close on Monday, August 7, 2023.

OPKO Health, Inc. plans to report operating and financial results for the three and six months ended June 30, 2023 after the close of the U.S. financial markets on Thursday, August 3, 2023.

Merit Medical Systems, Inc. (NASDAQ: MMSI), a leading global manufacturer and marketer of healthcare technology, today announced revenue of $320.1 million for the quarter ended June 30, 2023, an increase of 8.5% compared to the quarter ended June 30, 2022.

Iovance Biotherapeutics, Inc. announced oral and poster presentations reporting clinical and preclinical data for tumor infiltrating lymphocyte therapies at IASLC 2023 World Conference on Lung Cancer hosted by the International Association for the Study of Lung Cancer in Singapore, September 9-12, 2023.

Vizgen , the life science company dedicated to improving human health by visualizing single-cell spatial genomics information, today announced that it has installed its 100th MERSCOPE instrument in the Single Cell Genomics Core at the Baylor College of Medicine Department of Molecular and Human Genetics led by Dr. Rui Chen.

Hoth Therapeutics, Inc. today announced today that the first patient has been dosed in its Phase 2a clinical trial of HT-001 for the treatment of skin toxicities associated with Epidermal Growth Factor Receptor Inhibitors (EGFRi).

The European Commission (EC) approved Jardiance® (empagliflozin) for the treatment of adults with chronic kidney disease (CKD),8 Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) announced today.

Baxter International Inc. today announced that Vantive will be the name of the company’s proposed spinoff of its Renal Care and Acute Therapies businesses.